摘要
肝硬化是肝脏的一种弥漫性病理生理状态,被认为是各种肝损伤的最后阶段,特征为慢性炎症和纤维化,随后正常肝组织结构转换成结构异常结节、密集的纤维间隔,紧接着实质疲倦和肝脏组织的瓦解。由乙肝和(或)丙肝造成的酒精性肝病和慢性感染仍是世界范围肝硬化的主要症状。在漫长的15-30年期间,慢性肝疾病会导致肝硬化及其并发症。活性肝炎在炎症坏死再生中起着重要的作用,最终将导致肝硬化和原发性肝细胞癌。肝硬化的预后是高度可变的,受多个变量的影响,如病因、病情的严重程度、并发症和合并症的存在。在肝硬化晚期,生存率下降到1-2年。正确的先进性的诊断和不同小分子选择性治疗有助于理解肝纤维化的机制,这是肝硬化病理学驱动力,有助于用更严谨的方法来达到更有效的治疗方案。为防止肝功能进一步退化引起的纤维化常要求特异性治疗,即靶向治疗。因此,本文旨在评估以病理生理学为基础的肝硬化的诊断和治疗,用PubMed数据库搜寻从2011年至今的英文出版的相关文献。
关键词: 并发症;纤维症;肝硬化;肝脏;瞬间弹性成像
图形摘要
Current Drug Targets
Title:Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Volume: 17 Issue: 15
Author(s): Roberto Giulio Romanelli, Cristina Stasi
Affiliation:
关键词: 并发症;纤维症;肝硬化;肝脏;瞬间弹性成像
摘要: Cirrhosis is a diffuse pathophysiological state of the liver considered to be the final stage of various liver injuries, characterized by chronic necroinflammatory and fibrogenetic processes, with subsequent conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa, concomitant parenchymal exaustment and collapse of the liver tissue. Alcoholic liver disease and chronic infections due to HBV and/or HCV constitute the main causes of liver cirrhosis worldwide. During a lag time of 15 to 30 years, chronic liver diseases can lead to liver cirrhosis and its complications. Active hepatic inflammation plays a pivotal role in the inflammation- necrosis-regeneration process, which eventually leads to liver cirrhosis and hepatocellular carcinoma. Prognosis of liver cirrhosis is highly variable and influenced by several variables, such as etiology, severity of liver disease, presence of complications and comorbidities. In advanced cirrhosis, survival decreases to one or two years. Correct advanced diagnosis and selected treatment with different molecules may help in understanding mechanisms of fibrogenesis, the driving forces of cirrhosis’s pathogenesis, and the scrupulous approach to more effective therapeutic procedures. Prevention of fibrosis with further deterioration of liver function through specific treatments is always required, through the removal of the underlying causes of liver disease. Advanced liver disease, with subsequent complications, requires targeted treatment. Therefore, the aim of this review is to assess the diagnosis and treatment of liver cirrhosis on the pathophysiological bases, searching for relevant studies published in English using the PubMed database from 2011 to the present.
Export Options
About this article
Cite this article as:
Roberto Giulio Romanelli, Cristina Stasi , Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis, Current Drug Targets 2016; 17 (15) . https://dx.doi.org/10.2174/1389450117666160613101413
DOI https://dx.doi.org/10.2174/1389450117666160613101413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives
Current Pharmaceutical Design Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Vitamin E in Oxidant Stress-Related Cardiovascular Pathologies: Focus on Experimental Studies
Current Pharmaceutical Design A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature
Current Hypertension Reviews Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets Heat Shock Proteins: Mediators of Atherosclerotic Development
Current Drug Targets Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Isolated-Perfused Heart: The Preparation that has been used as a Research Tool for More than a Century
Drug Design Reviews - Online (Discontinued)